MPLT — MapLight Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $760.91m
- $700.43m
Annual income statement for MapLight Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 31.2 | 57.3 | 82.9 |
| Operating Profit | -31.2 | -57.3 | -82.9 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -30 | -55.7 | -77.6 |
| Net Income After Taxes | -30 | -55.7 | -77.6 |
| Net Income Before Extraordinary Items | |||
| Net Income | -30 | -55.7 | -77.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -30 | -55.7 | -77.6 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.725 | -1.34 | -1.87 |